SG11201508433TA - Therapeutic delivery vesicles - Google Patents

Therapeutic delivery vesicles

Info

Publication number
SG11201508433TA
SG11201508433TA SG11201508433TA SG11201508433TA SG11201508433TA SG 11201508433T A SG11201508433T A SG 11201508433TA SG 11201508433T A SG11201508433T A SG 11201508433TA SG 11201508433T A SG11201508433T A SG 11201508433TA SG 11201508433T A SG11201508433T A SG 11201508433TA
Authority
SG
Singapore
Prior art keywords
therapeutic delivery
delivery vesicles
vesicles
therapeutic
delivery
Prior art date
Application number
SG11201508433TA
Other languages
English (en)
Inventor
Andaloussi Samir El
Oscar WIKLANDER
Joel NORDIN
Edvard Smith
Karl-Henrik Grinnemo
Oscar Simonson
Original Assignee
Andaloussi Samir El
Oscar WIKLANDER
Joel NORDIN
Edvard Smith
Karl-Henrik Grinnemo
Oscar Simonson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20296661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201508433T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Andaloussi Samir El, Oscar WIKLANDER, Joel NORDIN, Edvard Smith, Karl-Henrik Grinnemo, Oscar Simonson filed Critical Andaloussi Samir El
Publication of SG11201508433TA publication Critical patent/SG11201508433TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01C—ROTARY-PISTON OR OSCILLATING-PISTON MACHINES OR ENGINES
    • F01C1/00—Rotary-piston machines or engines
    • F01C1/30—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members
    • F01C1/34—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members
    • F01C1/344—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member
    • F01C1/3441—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member the inner and outer member being in contact along one line or continuous surface substantially parallel to the axis of rotation
    • F01C1/3442—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member the inner and outer member being in contact along one line or continuous surface substantially parallel to the axis of rotation the surfaces of the inner and outer member, forming the working space, being surfaces of revolution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01C—ROTARY-PISTON OR OSCILLATING-PISTON MACHINES OR ENGINES
    • F01C21/00—Component parts, details or accessories not provided for in groups F01C1/00 - F01C20/00
    • F01C21/10—Outer members for co-operation with rotary pistons; Casings
    • F01C21/102—Adjustment of the interstices between moving and fixed parts of the machine by means other than fluid pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Fluid Mechanics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
SG11201508433TA 2013-04-12 2014-04-10 Therapeutic delivery vesicles SG11201508433TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1300271 2013-04-12
PCT/SE2014/000047 WO2014168548A2 (en) 2013-04-12 2014-04-10 Therapeutic delivery vesicles

Publications (1)

Publication Number Publication Date
SG11201508433TA true SG11201508433TA (en) 2015-11-27

Family

ID=20296661

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201508433TA SG11201508433TA (en) 2013-04-12 2014-04-10 Therapeutic delivery vesicles

Country Status (11)

Country Link
US (3) US11274139B2 (es)
EP (2) EP2983721B2 (es)
JP (3) JP6542197B2 (es)
AU (1) AU2014251388B2 (es)
CA (1) CA2910802A1 (es)
DK (1) DK2983721T4 (es)
ES (1) ES2662326T5 (es)
HK (1) HK1257101A1 (es)
PT (1) PT2983721T (es)
SG (1) SG11201508433TA (es)
WO (1) WO2014168548A2 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
JP6542197B2 (ja) 2013-04-12 2019-07-10 エヴォックス・セラピューティクス・リミテッド 治療的送達小胞
US10251934B2 (en) 2013-04-16 2019-04-09 Orbsen Therapeutics Limited Syndecan-2 compositions and methods of use
CA2949083C (en) 2014-05-18 2023-10-10 Children's Medical Center Corporation Methods and compositions relating to exosomes
GB201418562D0 (en) * 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
WO2016150884A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
KR101912310B1 (ko) * 2016-10-04 2018-10-26 주식회사 셀렉스라이프사이언스 페록시레독신 i 또는 ii 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 항산화용 약학적 조성물
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
WO2016178532A1 (ko) * 2015-05-04 2016-11-10 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법
KR101912313B1 (ko) * 2016-09-30 2018-10-26 주식회사 셀렉스라이프사이언스 Cre 재조합 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 표적 유전자의 조건적 녹아웃 대립유전자를 생성하기 위한 조성물
KR101900465B1 (ko) * 2016-10-13 2018-09-19 주식회사 셀렉스라이프사이언스 CRISPR-CAS family를 이용한 게놈 에디팅 툴을 엑소솜으로 전달하는 기술
KR101912315B1 (ko) * 2016-09-30 2018-10-26 주식회사 셀렉스라이프사이언스 Bax 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
KR101877010B1 (ko) * 2016-09-30 2018-08-09 한국과학기술원 super-repressor-IκB 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
JP2018520125A (ja) 2015-06-10 2018-07-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患の処置のためのエキソソームの使用
WO2017054086A1 (en) * 2015-10-01 2017-04-06 Exerkine Corporation Treatment of genetic myopathies using bioengineered exosomes
JP2018529340A (ja) * 2015-10-01 2018-10-11 ユニバーシティ・オブ・オタワ 核酸のエキソソームパッケージング
CA3004450A1 (en) 2015-11-18 2017-05-26 University Of Georgia Research Foundation, Inc. Neural cell extracellular vesicles
WO2017122095A1 (en) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552301A (en) * 2016-07-11 2018-01-24 Evox Therapeutics Ltd Metabolic drug loading of EVs
GB2552460A (en) * 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
CA3002520A1 (en) * 2016-09-30 2018-04-05 Cellex Life Sciences, Incorporated Compositions containing protein loaded exosome and methods for preparing and delivering the same
KR102120921B1 (ko) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Gba 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 고셔병 예방 및 치료용 약학적 조성물
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018173059A1 (en) 2017-03-21 2018-09-27 Exoprother Medical Ltd. Native cell derived vesicles containing tumor suppressor proteins for therapy
US20200392219A1 (en) * 2017-05-08 2020-12-17 Trustees Of Tufts College Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof
KR20200034668A (ko) 2017-05-08 2020-03-31 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 막 융합을 촉진시키기 위한 조성물 및 그의 용도
KR20200030084A (ko) 2017-07-14 2020-03-19 오르브센 테라퓨틱스 리미티드 씨디39 기질 줄기세포 단리 방법 및 용도
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
CA3072562A1 (en) * 2017-08-15 2019-02-21 Children's Medical Center Corporation Purified mesenchymal stem cell exosomes and uses thereof
WO2019035057A2 (en) * 2017-08-17 2019-02-21 Cellex Life Sciences, Incorporated EXOSOMES FOR TARGET-SPECIFIC DELIVERY AND METHODS OF PREPARATION AND ADMINISTRATION THEREOF
US20200206360A1 (en) * 2017-08-17 2020-07-02 Ilias Biologics Inc. Exosomes for target specific delivery and methods for preparing and delivering the same
WO2019038533A1 (en) 2017-08-21 2019-02-28 Resurgo Genetics Limited METHODS OF CHANGING TRANSCRIPTIONAL OUTPUT
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
TR201720642A2 (tr) * 2017-12-18 2019-07-22 Univ Yeditepe Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇
MX2020006430A (es) 2017-12-22 2020-09-17 Roche Innovation Ct Copenhagen As Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.
WO2019122277A1 (en) 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
TW201934750A (zh) 2017-12-22 2019-09-01 丹麥商羅氏創新中心哥本哈根有限公司 包含二硫代磷酸酯核苷間連結之間隙子(gapmer)寡核苷酸
GB201802163D0 (en) * 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
CN112272706A (zh) 2018-02-17 2021-01-26 旗舰先锋创新V股份有限公司 用于膜蛋白递送的组合物和方法
EP3758687A4 (en) * 2018-03-01 2022-03-30 Rhode Island Hospital EXOSOME TARGETING OF CD4+-EXPRESSING CELLS
GB201809622D0 (en) 2018-06-12 2018-07-25 Evox Therapeutics Ltd Engineering extracellular vesicles for affinity purification
KR20210045409A (ko) 2018-08-14 2021-04-26 에버사이트 게엠베하 표적 특이적 세포외 소포
EP3844274A1 (en) 2018-08-28 2021-07-07 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
US20230068547A1 (en) 2018-11-14 2023-03-02 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
EP3654215B1 (en) 2018-11-15 2021-06-30 Sternum Ltd. Applying control flow integrity verification in intermediate code files
US20210379192A1 (en) * 2019-01-25 2021-12-09 Mantra Bio, Inc. Skeletal muscle targeting moieties and uses thereof
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
AU2020298314A1 (en) * 2019-06-21 2022-02-03 Entelexo Biotherapeutics Inc. Platforms, compositions, and methods for therapeutics delivery
KR102553337B1 (ko) * 2019-08-20 2023-07-10 (주)메디톡스 표적 단백질로서 il-1 저해제를 코딩하는 폴리뉴클레오티드를 포함하는 재조합 세포로부터 유래한 세포외 소낭 및 그의 용도
EP4097474A4 (en) 2020-01-27 2024-03-27 Mantra Bio Inc NON-NATURALLY OCCURRING VESICLES COMPRISING A CHIMERIC VESICLE LOCALIZATION COMPONENT, METHODS OF PREPARATION AND USES THEREOF
EP4099984A4 (en) 2020-02-05 2024-05-01 Diadem Biotherapeutics Inc ARTIFICIAL SYNAPSES
US20230160864A1 (en) * 2020-02-12 2023-05-25 President And Fellows Of Harvard College Methods of measuring and purifying extracellular vesicles
US20230226118A1 (en) * 2020-03-17 2023-07-20 Ohio State Innovation Foundation Designer extracellular vesicles for treating excitotoxicity
CN111529504B (zh) * 2020-03-25 2023-01-10 西安组织工程与再生医学研究所 功能性嵌合凋亡小体及其制备方法和应用
CN111529505B (zh) * 2020-03-25 2023-04-11 西安组织工程与再生医学研究所 功能性嵌合凋亡小体及其制备方法和应用
KR20210124180A (ko) * 2020-03-31 2021-10-14 주식회사 일리아스바이오로직스 NF-κB 억제제의 엑소솜 기반 전달의 사용
KR102636371B1 (ko) * 2020-04-10 2024-02-19 한국과학기술연구원 신규 재조합 엑소좀 및 그의 용도
KR102341138B1 (ko) 2020-05-31 2021-12-21 주식회사 엑소코바이오 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법
CN111588704B (zh) * 2020-07-01 2023-04-11 西安组织工程与再生医学研究所 靶向响应性释放系统及其制备方法和应用
CN111803617A (zh) * 2020-07-16 2020-10-23 卡杜兰(广州)生命基因工程科技有限公司 一种内载微囊的干细胞系统与制备方法
KR20220101559A (ko) 2021-01-11 2022-07-19 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
KR20220106696A (ko) 2021-01-21 2022-07-29 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
CN113166724A (zh) * 2021-03-30 2021-07-23 深圳市创生芯科生物科技有限公司 从iPSC及其衍生物制备用于任何临床用途的外泌体的方法
EP4320234A2 (en) 2021-04-07 2024-02-14 Astrazeneca AB Compositions and methods for site-specific modification
AU2022260542A1 (en) * 2021-04-23 2023-10-19 Avulotion Ab Extracellular vesicles from mesenchymal stromal cells for treatment of diseases
CN113616811B (zh) * 2021-08-18 2023-12-05 南京中医药大学 一种载脂蛋白修饰的融合型多功能纳米囊泡及其制备方法和应用
WO2023102550A2 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
CN114848608B (zh) * 2022-05-17 2024-01-30 东南大学 一种蛋白或多肽递送载体及其制备方法与应用
EP4282951A1 (en) * 2022-05-25 2023-11-29 École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation, Nantes-Atlantique (ONIRIS) Method for obtaining extracellular vesicles from beta cells
US20240018480A1 (en) * 2022-07-15 2024-01-18 ExoTop Theragnostics Inc. Enhancement of extracellular vesicle production by lysosome inhibitor
CN117802045A (zh) * 2022-09-30 2024-04-02 北京恩康医药有限公司 一种工程化细胞外囊泡的构建及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
JP3693209B2 (ja) * 1996-04-11 2005-09-07 三菱化学株式会社 閉鎖小胞の製造方法
JP4487019B2 (ja) * 1998-03-31 2010-06-23 ランサス メディカル イメージング インコーポレイテッド 血管新生疾患を画像化するための薬剤
FR2788780B1 (fr) * 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
JP4662708B2 (ja) 2001-08-17 2011-03-30 エクソセラ・エルエルシー エクソゾームにタンパク質を標的化する方法および組成物
IL161296A0 (en) * 2001-10-13 2004-09-27 Asterion Ltd Glycosylphosphatidylinositol containing polypeptides
JP2009501128A (ja) * 2005-01-20 2009-01-15 ユニバーシティー オブ ロチェスター 炎症疾患および炎症障害の研究および処置のための組成物および方法
EP2117305A4 (en) * 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE
EP2350320A4 (en) † 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES
EP2408474B1 (en) * 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP3569254B1 (en) * 2009-04-17 2022-07-20 Oxford University Innovation Limited Composition for delivery of genetic material
WO2011097633A2 (en) * 2010-02-08 2011-08-11 Board Of Regents, The University Of Texas System Egf receptor mimicking peptides
US20140004601A1 (en) * 2010-12-20 2014-01-02 Agency For Science, Technology And Research Method of purifying exosomes
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20130028895A1 (en) * 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
JP6542197B2 (ja) 2013-04-12 2019-07-10 エヴォックス・セラピューティクス・リミテッド 治療的送達小胞

Also Published As

Publication number Publication date
DK2983721T3 (en) 2018-03-19
WO2014168548A8 (en) 2015-01-29
US20160137716A1 (en) 2016-05-19
CA2910802A1 (en) 2014-10-16
PT2983721T (pt) 2018-03-13
ES2662326T3 (es) 2018-04-06
US11649272B2 (en) 2023-05-16
EP2983721B2 (en) 2021-01-20
EP2983721A2 (en) 2016-02-17
JP6999601B2 (ja) 2022-02-04
US20230111666A1 (en) 2023-04-13
EP2983721B1 (en) 2018-02-21
AU2014251388B2 (en) 2017-03-30
JP2016516768A (ja) 2016-06-09
US11274139B2 (en) 2022-03-15
US20200207833A1 (en) 2020-07-02
ES2662326T5 (es) 2021-08-04
AU2014251388A1 (en) 2015-11-12
HK1257101A1 (zh) 2019-10-11
JP2022058390A (ja) 2022-04-12
WO2014168548A2 (en) 2014-10-16
WO2014168548A3 (en) 2014-12-04
JP6542197B2 (ja) 2019-07-10
JP2019167378A (ja) 2019-10-03
DK2983721T4 (da) 2021-02-01
EP3335721A1 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
HK1257101A1 (zh) 治療性遞送囊泡
HK1221672A1 (zh) 鼻腔給藥
HK1211517A1 (en) Drug delivery device
HK1211520A1 (en) Drug delivery device
IL245544A0 (en) drug delivery system
SG11201508647UA (en) Drug delivery device
EP2961469A4 (en) DEVICE FOR DELIVERY OF MEDICAMENT
HK1211519A1 (en) Drug delivery device
GB201313782D0 (en) Drug delivery device
IL244286B (en) Drug delivery device
GB201308917D0 (en) Delivery
SG11201600371XA (en) Drug delivery device
HK1219451A1 (zh) 藥物輸送裝置
HK1219682A1 (zh) 藥物輸送裝置
HK1219450A1 (zh) 藥物輸送裝置
GB201308440D0 (en) Therapeutic
HK1219685A1 (zh) 藥物輸送裝置
HK1219681A1 (zh) 藥物輸送裝置
HK1221412A1 (zh) 囊泡
HK1219680A1 (zh) 藥物輸送裝置
GB2519596B (en) Medicament Delivery device
GB201318668D0 (en) Sonosensitive therapeutic
HK1221921A1 (zh) 藥物輸送裝置
HK1223052A1 (zh) 藥物輸送裝置
IL245007A0 (en) Drug release device